|Bid||50.05 x 2200|
|Ask||50.29 x 800|
|Day's range||50.16 - 51.42|
|52-week range||38.48 - 61.71|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||11.55|
|Earnings date||26 July 2022 - 01 Aug 2022|
|Forward dividend & yield||1.60 (3.17%)|
|Ex-dividend date||12 May 2022|
|1y target est||59.33|
For a stock to be a strong long-term buy, investors need to have confidence that its business will be able to grow indefinitely. Both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are examples of companies that continue to thrive today due to the pandemic with their highly successful COVID-19 vaccines generating billions in sales for their respective companies. COVID-19 revenue has resulted in surging revenue for Pfizer.
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.